Most importantly, cut-off values for positivity (e.g. >1%, >10%, >50%), the precise cellular origin of PD-L1 expression (tumor cells, immune cells or the combination of both (combined positivity score, CPS)) and technical issues strongly vary between studies, limiting a wide-ranging clinical implementation of potential (24). The gene discussed is CD274; the disease is neoplasm.